Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine

Alberto D’Angeloa Department of Life Sciences, University of Bath, Bath, UK;b Department of Oncology, Royal United Hospital, Bath, UKCorrespondence[email protected]

https://orcid.org/0000-0001-8417-9172

Martina Catalanoc School of Human Health Sciences, University of Florence, Florence, Italy

Raffaele Concad Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Vulture, Potenza, Italy;e Department of Oncology, San Bortolo General Hospital, Vicenza, Italy

Roberto Petriolif Department of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Siena, Italy

Francesca Siminonatoe Department of Oncology, San Bortolo General Hospital, Vicenza, Italy

Alessandro Cappettae Department of Oncology, San Bortolo General Hospital, Vicenza, Italy

Giandomenico Roviellog Department of Health Sciences, University of Florence, Florence, Italy

Monica Ramelloh Oncology Unit, Department of Medical, Surgical, & Health Sciences, University of Trieste, Trieste, Italy

show all

Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date